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Introduction
Lymphomas account for 3.5% of all malignant neo-
plasms in females. Non-Hodgkin’s lymphomas (NHL)
represent 70–80% of all lymphomas. NHL can involve
extranodal sites, most often the gastrointestinal tract
and skin [1]. Primary NHL of the vagina is extremely
rare. Only 0.5% of extranodal lymphomas in women
are likely to originate in the female genital tract [1,2].
We describe a case of primary NHL of the vagina
(stage IEA) treated successfully using chemotherapy
alone. The associated literature is also discussed.
Case Report
A 34-year-old female virgin presented with a 3-month
history of irregular vaginal bleeding and pelvic pain.
She had no fever, weight loss or night sweats. As the
patient was a virgin, vaginal examination could not 
be been performed. Transabdominal ultrasonographic
examination revealed a 7 × 6-cm solid, homogenous,
regular-shaped mass confined to the cervicovaginal
junction, with no extension to the pelvic wall or other
related structures (Figure 1).
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Accepted: February 13, 2008 Figure 1. Ultrasound image of the pelvic mass (arrows).
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Abdominopelvic magnetic resonance imaging show-
ed diffuse enlargement of the cervix and vagina, which
exhibited homogenous intermediate signal intensity and
internal necrosis, without destruction of the endome-
trial lining of the uterus. On admission, the following
laboratory parameters were noted: white blood cell
count 8.0 × 103/L (normal range, 4.5–11.0 × 103/L), he-
moglobin 15 g/dL (normal range, 13.5–18 g/dL), plate-
let count 240 × 103/L (normal range, 150–400 × 103/L),
segmented leukocytes 0.65 (normal range, 0.4–0.70),
lymphocytes 0.30 (normal range, 0.29–0.44), sedimen-
tation rate 8 mm/hr. The serum biochemistry profile
was completely normal. Tumor markers were within the
normal range. Based on the physical examination and
laboratory findings, a surgical exploration was planned,
with a suspected diagnosis of cervical myoma.
During laparotomy, the uterus and both ovaries were
seen as normal in shape, but a bulky, solid, fixed, irreg-
ular mass was seen at the cervicovaginal junction, ex-
panding throughout the whole vagina and parametrium,
extending to the pelvic side walls. The uterine corpus
and cervix were seen just above this mass. It was revealed
that the tumoral mass originated from the cervicovagi-
nal area and that all other visceral organs and the peri-
toneal area were normal. The mass had no obvious
surgical cleavage, and after sharp and blunt dissection,
it was determined to be unresectable and could not be
removed completely. After multiple biopsies, the oper-
ation was stopped. Histopathologic diagnosis identi-
fied the tumor as a diffuse large B-cell NHL. There was
no component of low-grade lymphoma suggestive of a
mucosa-associated lymphoid tissue lymphoma origin
(Figure 2).
Based on the Ann Arbor system used for staging NHL,
the patient was diagnosed with IEA primary vaginal
large B-cell NHL disease. She was treated with six cycles
of a CHOP (cyclophosphamide, doxorubicin, vincri-
stine and prednisone)-containing chemotherapy regime.
During the treatment period, no hematologic or other
organ system-related side effects developed. She received
no radiation therapy.
The patient was treated using this approach for 40
months post-diagnosis, after which the tumor had com-
pletely disappeared and there was no further clinical
evidence of the disease.
Discussion
Although secondary involvement of the female genital
organs can be seen in up to 40% of disseminated lym-
phomas, primary genital lymphomas are rarely encoun-
tered. They are most commonly localized in the ovaries
(49%), uterus (29%) and Fallopian tubes (11%) [3].
Primary vaginal lymphomas are very rare. Chorlton 
et al reviewed 9,500 cases of lymphomas in women and
found only four cases of primary vaginal lymphomas, i.e.
an incidence of 1 in 2,375 cases [4]. Ten cases of primary
vaginal diffuse large B-cell lymphomas were reported
in the literature between 1994 and 2007 (Table).
Vaginal lymphomas may occur in patients of a wide
range of ages (20–80 years). The most common his-
tologic subtype is diffuse large B-cell lymphoma. Clini-
cal symptoms usually include vaginal bleeding (70%),
perineal discomfort (40%), and persistent vaginal dis-
charge (20%). An abdominal or pelvic mass may be
found on clinical examination. Fever, night sweats and
weight loss are unusual symptoms. Cervical cytology 
is usually negative. Colposcopic biopsy may give false
negative results [1,2]. Our patient was 34 years old
and presented with abnormal vaginal bleeding and
pelvic pain.
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Figure 2. Histologic examination of the samples. (A) A low magnification photomicrograph of the infiltrate showing the 
distinct nodular architecture (original magnification ×40). (B) At high magnification the infiltrate is composed of a mixture
of small cleaved and large lymphocytes (original magnification ×400).
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Histopathologic evaluations can be used to diagnose
NHL. Computerized tomography and magnetic reso-
nance imaging are also useful for diagnosis and staging,
but their specificities are low [9].
Malignant mixed Müllerian tumor, epithelioid leio-
myosarcoma, degenerative myoma, endometrial stromal
tumors including endometrial stromal sarcoma, mela-
noma and extra-osseous Ewing’s sarcoma/primitive
neuroectodermal tumor should be kept in mind in the
differential diagnosis of vaginal NHL [6]. In our case,
we performed laparotomy with the suspected diagnosis
of cervical myoma, but morphologic and phenotypic
features supported a diagnosis of a diffuse low-grade
malignant NHL, consistent with a diffuse large B-cell
lymphoma.
Because of its rarity, there is no established treatment
protocol for primary NHL of the vagina. According to
the literature, the mainstay of the treatment for primary
genital lymphomas is radiotherapy alone, or in combi-
nation with surgery and/or chemotherapy [7,8]. The effi-
cacy and safety of chemotherapy as first-line therapy is
still debatable. Höffkes et al reported a complete patho-
logic and clinical response in one case of NHL of the
vagina stage IEA after CHOP chemotherapy [16]. Similar
results were obtained by Engin et al [10]. Garavaglia
and colleagues reported on a patient with stage IEA NHL
of the vagina who underwent complete remission with
MACOP-B (methotrexate, doxorubicin, cyclophospha-
mide, vincristine, prednisone, and bleomycin) alone [11].
The destruction of reproductive organs and result-
ing infertility is a significant disadvantage of radiother-
apy in young women. Therefore, cytotoxic chemotherapy
should be considered for these patients who wish to pre-
serve their fertility. Even if the tumor does not respond to
cytotoxic chemotherapy, salvage radiotherapy has been
shown to be successful in the majority of cases [12].
Signorelli et al treated three patients with NHL of the
vagina using a CHOP regime and observed two complete
responses, though one patient with persistent disease
after chemotherapy needed external beam radiotherapy
to obtain a complete clinical response [12]. In this re-
port, the patient underwent CHOP chemotherapy (six
weekly cycles) which was well tolerated and completed
without adverse effects. Radiation therapy was not given.
The prognosis for extranodal lymphomas is usually
poorer than that for nodal lymphomas because of inac-
curate or delayed diagnoses [1]. However, if pelvic lym-
phomas are diagnosed at earlier stages, the prognosis
can be excellent compared with other gynecologic malig-
nancies, with a 5-year survival rate ranging from 80–90%
[13,14].
In conclusion, because of the rarity of primary NHL
of the vagina, the optimal therapy is unknown. For young
patients with primary large B-cell NHL of the lower
female genital tract who wish to retain their fertility,
chemotherapy alone may be the treatment of choice.
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